Search Clinical Trials
The BU-CTSI is a center of expertise providing tools, services and resources to clinical investigators, maximizing the impact of discoveries & speeding the translation of research into improved patient care
184 matching studies
Study is registered in ResearchMatch  Sponsor Condition of Interest |
|---|
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sc1
Novartis Pharmaceuticals
Scleroderma, Diffuse
The purpose of this study is to evaluate the efficacy, safety and tolerability of
rapcabtagene autoleucel (administered once following lymphodepletion) in participants
with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab. expand
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab. Type: Interventional Start Date: Oct 2024 |
|
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupu1
Novartis Pharmaceuticals
Lupus Erythematosus, Systemic
Lupus Nephritis
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene
autoleucel (administered once following lymphodepletion) in patients with active,
refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN). expand
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN). Type: Interventional Start Date: Sep 2024 |